Overview
Widely used across Eastern Europe and Asia, and one of the few peptide products with Cochrane systematic reviews. Those reviews are not favourable, which makes this a useful case study in how volume of use and quality of evidence can diverge.
Limited or non-US approvalApproved in many countries; unapproved and not lawfully marketed in the US.
| Regulatory status | Approved in around 40 countries for stroke, dementia and traumatic brain injury. Not approved in the US, UK or most of Western Europe. |
|---|---|
| Drug class | Porcine brain-derived peptide preparation — a mixture, not a single molecule |
| Route | Intravenous or intramuscular |
| Half-life | Not applicable — heterogeneous mixture |
| Evidence rating |
3/5 Moderate
Evidence rating 3 out of 5: Moderate
Small or early-phase human trials, or good controlled topical human data. |
| Studied in | Numerous randomized trials in acute ischemic stroke, vascular dementia, Alzheimer disease and traumatic brain injury; multiple Cochrane systematic reviews. |
How it works
Enzymatically processed porcine brain protein yielding low-molecular-weight peptides and amino acids with claimed neurotrophic activity mimicking endogenous factors such as BDNF and GDNF. The exact active constituents are not fully defined.
Evidence base
Rated 3 of 5 — Moderate. Small or early-phase human trials, or good controlled topical human data.
- Unusual for a peptide product: enough trials to be systematically reviewed. The reviews are the key evidence.
Benefits & potential uses
Bars indicate how well each claim is supported: three = strong human evidence, two = moderate, one = preliminary or preclinical.
-
Some cognitive benefit signals in vascular dementia Preliminary
Meta-analyses of dementia trials report modest cognitive score improvements, though effect sizes are small and heterogeneity is high.
-
Large accumulated clinical experience Moderate evidence
Decades of use across many countries with an extensive, if uneven, literature.
-
Neurotrophic activity in preclinical models Preliminary
Animal work supports neuroprotection and neurogenesis effects.
Risks, cons & cautions
Bars indicate seriousness: three = serious or common, two = moderate, one = minor.
-
Cochrane review found no benefit in acute stroke Serious
The systematic review concluded there was no evidence of benefit on death or dependence — the outcomes that matter most.
-
Possible increase in serious adverse events Serious
The same review raised a signal for non-fatal serious adverse events, though confidence intervals were wide.
-
Porcine biological source Moderate evidence
Carries theoretical transmissible agent concerns and is unacceptable to some patients on religious grounds.
-
Undefined composition Moderate evidence
A mixture whose active components are not fully characterised, complicating batch consistency and mechanism attribution.
-
Anaphylaxis and hypersensitivity Moderate evidence
Reported with a foreign-protein-derived product.
-
Trial quality and publication bias concerns Serious
Much of the positive literature comes from a limited set of investigators and sponsors.
Who should avoid it
- Epilepsy (relative — seizure reports exist)
- Severe renal impairment
- Pregnancy
- Known protein hypersensitivity
If used under medical supervision, monitor
- Renal function
- Allergic reaction observation during infusion
- Cognitive assessment scales
Regulatory & legal status
Approved in many countries; unapproved and not lawfully marketed in the US.
Infographic
Where to read further
We link to live literature searches rather than a frozen citation list, so you always see current results — including anything published after our last review.
- PubMed — all published literature on Cerebrolysin
- PubMed — randomized controlled trials only
- ClinicalTrials.gov — registered human trials
Related peptides in Cognitive & Neurological
Terms used on this page
- GRADE Certainty of Evidence
- GRADE rates the certainty of evidence for each outcome as high, moderate, low or very low, separately from the size of the effect and from the strength of any recommendation built on it.
- Systematic Review
- A systematic review answers a defined question using a prespecified protocol, an explicit multi-database search, stated eligibility criteria and formal risk-of-bias assessment, unlike a narrative review.
- Amino Acid
- An amino acid is the monomer unit of a peptide, built from an alpha carbon carrying an amino group, a carboxyl group, a hydrogen and a variable side chain that defines its chemistry.
- Brain-Derived Neurotrophic Factor (BDNF)
- BDNF is a neurotrophin that signals through the TrkB receptor to support neuronal survival, dendritic growth and the late, protein-synthesis-dependent phase of synaptic potentiation.
- Heterogeneity (I²)
- Heterogeneity is variation in the true effects across studies in a meta-analysis, and I-squared estimates the share of observed variation that exceeds what sampling error alone would produce.
- Meta-Analysis
- A meta-analysis statistically combines effect estimates from several studies into a pooled estimate, weighting each by its precision, and is a method rather than a grade of evidence.
This page is educational information, not medical advice. It cannot account for your medical history, medications, or risk factors. Do not start, stop or change any treatment based on it. Speak to a qualified healthcare professional who knows your case.